Please login to the form below
heart failure
This page shows the latest heart failure news and features for those working in and with pharma, biotech and healthcare.
Novartis follows Pfizer and freezes US prices this year
Novartis’decision to keep pricing steady has been helped by a rosy set of second-quarter results, with recent launches Cosentyx (secukinumab) for psoriasis and heart failure therapy Entresto (sacubitril and
Latest news
-
J&J’s Invokana aces diabetic kidney disease trial, setting up filings
found it cut hospitalizations due to heart failure – but in the meantime has seen sales go into reverse.
-
J&J says real-world data finds no amputation risk for Invokana
AZ is still waiting for data read-outs from its cardiovascular outcomes study (due in 2019), but presented real-world evidence for a benefit on heart failure rates last year.
-
Orphan drugs dominate UK Prix Galien shortlist, medtech debuts
The most recent winner of the Innovative Product Award, at the 2016 UK Prix Galien, was Novartis’Entresto – the first new treatment for heart failure in 15 years.
-
Real-world data finds patients feel better on Entresto, says Novartis
In that context, improving patients’symptoms and QoL in a progressive disease such as heart failure is important, as is identifying when their health starts to deteriorate. ... s Jardiance (empagliflozin), as around a third of patients with heart
-
Pfizer drug gets speedy FDA review for rare heart failure complication
Pfizer drug gets speedy FDA review for rare heart failure complication. ... Transthyretin cardiomyopathy is a fatal and underdiagnosed condition associated with progressive heart failure, with no FDA-approved treatments, and tafamidis chalked up a
More from news
Approximately 34 fully matching, plus 226 partially matching documents found.
Latest Intelligence
-
No incentive for a cure
Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to the progress in modern medicine.
-
Can value-based healthcare take off and reach for the skies?
costs. It was then backed with a ‘no response-no payment’contract. It has also struck novel reimbursement packages with its heart failure therapy Entresto and its psoriasis treatment Cosentyx.
-
Deal Watch February 2017
Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
-
Deal Watch January 2017
1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.
-
A healthy challenge
All told, 50 million people in the EU are afflicted by conditions such as diabetes, congestive heart failure, chronic obstructive pulmonary disease and asthma, and in 2013 more than 1.2m
More from intelligence
Approximately 1 fully matching, plus 18 partially matching documents found.
Latest appointments
-
uniQure appoints chief executive officer
for congestive heart failure and Huntington's disease into the clinic.”.
-
Cardio3 BioSciences appoints Warren Sherman chief medical officer
Sherman has over 30 years' cardiology experience, with a focus on cell-based therapies for treating patients post-myocardial infarction and with heart failure.
-
Acorda appoints new CFO
pain and heart failure.
-
Cardioxyl appoints Novartis scientist as chief medical officer
Dr Foo was responsible for the establishment and execution of multiple programmes in heart failure and the cardiorenal space at Novartis and will use her experience to lead research at ... Her unique combination of both early- and late-stage
-
CytomX makes senior changes following Pfizer deal
Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he worked in the development of products in nephrology, diabetes and heart failure.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Case Study: Qualitative research with payers in low and middle income countries
Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
